Lidocaine for systemic sclerosis: a double-blind randomized clinical trial
2011

Lidocaine for Treating Scleroderma

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): Riera Rachel, Andrade Luís EC, Souza Alexandre WS, Kayser Cristiane, Yanagita Edison T, Trevisani Virgínia FM

Primary Institution: Universidade Federal de São Paulo - Escola Paulista de Medicina

Hypothesis

Is lidocaine effective and safe for treating systemic sclerosis?

Conclusion

Lidocaine did not show efficacy in treating scleroderma despite previous studies suggesting otherwise.

Supporting Evidence

  • 66.7% of the placebo group showed improvement in skin score compared to 50% in the lidocaine group.
  • No significant adverse effects were reported in either group.
  • Both groups reported similar improvements in subjective self-assessment.

Takeaway

This study tested if lidocaine could help people with a disease called scleroderma, but it didn't work as hoped.

Methodology

A double-blind randomized clinical trial with 24 patients receiving either lidocaine or placebo over three cycles.

Potential Biases

Low risk of bias due to randomization and blinding.

Limitations

The study included patients with more than two years since the first symptom and used a fixed dosage of lidocaine.

Participant Demographics

12 males and 12 females, aged 40-41 years on average.

Statistical Information

P-Value

0.408

Statistical Significance

p = 0.408

Digital Object Identifier (DOI)

10.1186/1750-1172-6-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication